Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

BackgroundThe MET proto-oncogene (MET) plays a crucial role as an oncogenic driver gene in non-small cell lung cancer (NSCLC). At present, numerous types of MET exon 14 (METex14) skipping mutation have been identified, but different splice variants often exhibit varying treatment responses. There is...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yinyin Xue, Wen Li, Pengfei Li, Kaili Huang, Qinghua Zhou, Qiang Wu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-03-01
Serija:	Frontiers in Pharmacology
Teme:	novel MET exon 14 skipping mutation EGFR-TKI resistance advanced lung adenocarcinoma savolitinib sustained clinical response
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1489696/full
Oznake:	Označite Brez oznak, prvi označite!